CompletedPhase 3NCT02563327

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centers for Disease Control and Prevention
Principal Investigator
Rada Savic, PhD
University of San Francisco School of Pharmacy, San Francisco, CA
Intervention
Rifapentine(drug)
Enrollment
53 enrolled
Eligibility
18 years · All sexes
Timeline
20162021

Study locations (3)

Collaborators

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02563327 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials